01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Engineered multicellular living organisms, comprising human cells, for scientific and research use Engineered multicellular living organisms, comprising human cells, for medical purposes
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Custom synthesis of engineered multicellular organisms for scientific and medical research Research and development in the field of biotechnology and human and animal health; medical research pertaining to human and animal health Licensing of intellectual property covering engineered multicellular organisms for others
3.
Biopolymer-Based Preservation of Perishable Products
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
In some embodiments, the present invention provides methods for making resorbable ear tubes including the steps of providing a silk fibroin solution, and forming a silk ear tube from the silk fibroin solution, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbable. In some embodiments, the present invention also provides methods for treating otitis media including the step of introducing a silk ear tube into the ear canal of a subject, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbed by the subject.
A61L 29/14 - Materials characterised by their function or physical properties
A61F 11/00 - Methods or devices for treatment of the ears or hearing sense Non-electric hearing aidsMethods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing senseProtective devices for the ears, carried on the body or in the hand
The present application relates to silk fibroin-based materials, methods for making and using the same. Provided materials exhibit shape memory characteristics while showing comparable or better volumetric swelling, biocompatibility and/or degradability when compared to current memory polymers derived from either natural or synthetic materials.
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
D01F 4/02 - Monocomponent artificial filaments or the like of proteinsManufacture thereof from fibroin
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61L 31/14 - Materials characterised by their function or physical properties
C08J 9/00 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
6.
MULTI-LAYER BIOMATERIAL FOR TISSUE REGENERATION AND WOUND HEALING
The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects.
A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
A61L 27/58 - Materials at least partially resorbable by the body
B29C 39/00 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor
7.
COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING COMPLICATIONS OF OBESITY
Provided herein are compositions and methods for treating, preventing, and reducing the risk of obesity and related diseases and conditions. In particular, provided herein is a composition comprising a dry powder of fruits and vegetables and uses thereof.
This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
B23K 26/361 - Removing material for deburring or mechanical trimming
B23K 26/402 - Removing material taking account of the properties of the material involved involving non-metallic material, e.g. isolators
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
11.
Optimal multi-dimensional data compression by tensor-tensor decompositions tensor
A tensor decomposition method, system, and computer program product include compressing multi-dimensional data by truncated tensor-tensor decompositions.
H03M 7/00 - Conversion of a code where information is represented by a given sequence or number of digits to a code where the same information is represented by a different sequence or number of digits
H03M 7/30 - CompressionExpansionSuppression of unnecessary data, e.g. redundancy reduction
G06F 16/174 - Redundancy elimination performed by the file system
H03M 7/40 - Conversion to or from variable length codes, e.g. Shannon-Fano code, Huffman code, Morse code
Methods, tip assemblies and kits are provided for introducing material into cells. The tip assemblies include an attachment portion, a channel portion, and a constriction that function to reduce fluid pressure as a fluid passes through the constriction portion from the channel portion, whereby the tip assemblies form pores in the membranes of cells and introduce material into the cells. The material includes for example one selected from the group of: an inorganic compound, a drug, a genetic material, a protein, a carbohydrate, a synthetic polymer, and a pharmaceutical composition.
Provided herein are compositions and methods for treating, preventing, and reducing the risk of obesity and related diseases and conditions. In particular, provided herein is a composition comprising a dry powder of fruits and vegetables and uses thereof.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
A61K 36/23 - Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
The present application discloses biopolymer-based ink formulations that are useful for inkjet printing and other applications. Related methods are also disclosed.
A system and method, for measuring phase delay and amplitude of a near infrared signal emanating from tissue of an animal subject in response a near infrared signal input to such tissue, operate by processing a signal from an optical detector and a corresponding signal from an optical detector emulation circuit. In some aspects, the processed signals are fed into a phase delay detection system that provides an output thereof a digital measure of the phase delay of the received optical signal.
A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
Protein-protein imprinting of silk fibroin is introduced as a rapid, high-fidelity, and/or high-throughput method for the fabrication of nanoscale structures in silk films, through controlled manipulation of heat and/or pressure. High resolution imprinting on conformal surfaces is also demonstrated.
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor
C08L 89/00 - Compositions of proteinsCompositions of derivatives thereof
B41C 1/10 - Forme preparation for lithographic printingMaster sheets for transferring a lithographic image to the forme
B82Y 40/00 - Manufacture or treatment of nanostructures
20.
NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME
The present invention includes methods of improving proteolytic stability of a polypeptide, comprising alkylating at least one selected from the group consisting of a N-terminus amino group, the NH group of the N-terminus first internal amide bond, another primary amino group, a thiol group and a thioether group within the polypeptide. The present invention further includes polypeptides incorporating such chemical modifications.
Methods, tip assemblies and kits are provided for introducing material into cells. The tip assemblies include an attachment portion, a channel portion, and a constriction that function to reduce fluid pressure as a fluid passes through the constriction portion from the channel portion, whereby the tip assemblies form pores in the membranes of cells and introduce material into the cells. The material includes for example one selected from the group of: an inorganic compound, a drug, a genetic material, a protein, a carbohydrate, a synthetic polymer, and a pharmaceutical composition.
Described herein are microfluidic devices and systems for high density cell culture and/or high throughput cell assays. Methods of using the same are also provided herein. In some embodiments, the microfluidic devices and systems described herein provide rapid and automated trapping of single embryos in ordered arrays.
Provided herein are methods and compositions for the treatment of wounds in a mammalian subject. Particularly, novel bioactive polypeptides are provided that promote tissue repair and regeneration, including the activation of/stimulation of wound healing and wound closure, stimulate keratinocyte and endothelial cell motility and/or proliferation.
C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/485 - Epidermal growth factor [EGF], i.e. urogastrone
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A segregated polymeric material is described that includes a silicon-based hydrophobic polymer and a copolymer comprising a silicon-based hydrophobic polymer and a hydrophilic segment, wherein the copolymer has been segregated to a surface of the material by contacting the surface with an aqueous solution. The segregated polymeric material can be used to improve the wettability and decrease the protein adsorption of a surface.
The present invention provides, among other things, a silk ceramic material having enzymatically cross-linked amino acid side chains to generate injectable and flexible foam ceramics. Provided are compositions and methods of producing soft, flexible ceramic foam with silk polymeric crosslinking to serve as binders. Materials have applications in osteochondral and dental replacement and repair.
A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
26.
FEEDBACK CORRECTION IN SUB-RESONANT TAPPING MODE OF AN ATOMIC FORCE MICROSCOPE
A method of carrying out sub-resonant tapping in an atomic force microscope includes causing a probe that is disposed above a sample to be translated in a direction parallel to a horizontal plane defined by the sample and to oscillate in a vertical direction that is perpendicular to the horizontal plane about an equilibrium line that is separated from the horizontal plane by a vertical offset. As a result, the probe repeatedly taps a surface of the sample. Each tap begins with a first contact of the probe on the surface followed by a progressive increase in force exerted by the sample on the probe until a peak force is attained. The vertical offset is controlled by relying at least in part on a feature other than the peak force as a basis for controlling the vertical offset.
This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to compounds, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
28.
Methods of generating anti-inflammatory stem cells
The invention provides compositions and methods for treating inflammatory diseases, such as cardiac or hepatic inflammatory diseases, involving the use of parasite-derived neurotrophic factor (PDNF), or fragment of PDNF.
The present application relates to silk fibroin-based materials, methods for making and using the same. Provided materials exhibit shape memory characteristics while showing comparable or better volumetric swelling, biocompatibility and/or degradability when compared to current memory polymers derived from either natural or synthetic materials.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
D01F 4/02 - Monocomponent artificial filaments or the like of proteinsManufacture thereof from fibroin
A61L 31/14 - Materials characterised by their function or physical properties
C08J 9/00 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61B 17/00 - Surgical instruments, devices or methods
C08H 1/00 - Macromolecular products derived from proteins
30.
MACROPOROUS CHITOSAN-POLYACRYLAMIDE HYDROGEL MICROSPHERES AND PREPARATION THEREOF
A macroporous polymeric hydrogel microsphere that contains polyacrylamide and chitosan. The hydrogel microsphere, having a diameter of 50-250 µm and an average pore size of 1-60 nm, is capable of transporting biomolecules conjugated to it. Also disclosed is a method of fabricating the microsphere based on a micromolding technique utilizing surface tension-induced droplet formation followed by photo-induced polymerization.
Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent, methods, compositions and kits having a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes at least one or a plurality of disease agents that are toxins, for example at least one of a Botulinum toxin or an Anthrax toxin.
An approach to communication of a quantized value includes communicating one or more parameters characterizing a distribution of the values, and then repeatedly quantizing values according to the distribution and communicating the transmitted values. In some examples, the quantizing of the values is according to a maximum-entropy codebook determined from the distribution (or from the parameters characterizing the distribution). In one application, a network communication method communicates link state values among nodes of the network using this approach to communication of quantized values. For example, link state information is distributed among nodes of the network by distributing parameters characterizing distributions of the link state values for particular links, and quantizing the link state values according to codebooks determined from the parameters. In some examples, the parameters characterizing the distributions are distributed less frequently than the quantized values.
Compositions and methods are provided for preventing, ameliorating, or treating a disease caused by a species of bacterial genus Vibrio, for example, cholera caused by V. cholerae, the compositions containing two or more strains of lytic bacteriophage that infect and kill Vibrio cells. The bacteriophage are virulent, which replicate intracellularly and lyse and kill the bacteria. Use of two or more strains in a single treatment, as a result of a rate of mutation of the bacteria to simultaneous resistance to all of the bacteriophage to be so low as to be negligible, reduces appearance of phage-resistant bacteria to statistical negligibility. Normal human microbial flora species were not affected. In alternative embodiments of the method and the composition, antibiotic agents or other treatment agents can be administered with a cocktail of the plurality of bacteriophage strains.
A polymeric hydrogel microparticle that contains polyacrylamide and chitosan, the chitosan uniformly incorporated in a polyacrylamide matrix. The microparticle, having a coefficient variation of 0 to 2% and containing macropores with an average size of 1 to 60 nm, is capable of transporting biomolecules conjugated to it. Also disclosed are a method of fabricating such a microparticle in a micromold via photo-induced radical polymerization and a one-pot method of conjugating biomolecules to polymeric hydrogel microparticles.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing information and an online resource in the nature of a website in the field of nutrition and physical health directed to out-of-school youth organizations to assist them in coordinating and establishing principles for reducing childhood obesity
A keyboard entry system for use in a touch screen display in which a user touches the display to move a keyboard on the display. The user moves the keyboard until a desired key lies under a fixed cursor. To type the key, the user lifts his finger.
G06F 3/042 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means by opto-electronic means
G06F 3/0488 - Interaction techniques based on graphical user interfaces [GUI] using specific features provided by the input device, e.g. functions controlled by the rotation of a mouse with dual sensing arrangements, or of the nature of the input device, e.g. tap gestures based on pressure sensed by a digitiser using a touch-screen or digitiser, e.g. input of commands through traced gestures
G06F 3/023 - Arrangements for converting discrete items of information into a coded form, e.g. arrangements for interpreting keyboard generated codes as alphanumeric codes, operand codes or instruction codes
G06F 3/041 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
G06F 3/0481 - Interaction techniques based on graphical user interfaces [GUI] based on specific properties of the displayed interaction object or a metaphor-based environment, e.g. interaction with desktop elements like windows or icons, or assisted by a cursor's changing behaviour or appearance
G06F 3/0489 - Interaction techniques based on graphical user interfaces [GUI] using specific features provided by the input device, e.g. functions controlled by the rotation of a mouse with dual sensing arrangements, or of the nature of the input device, e.g. tap gestures based on pressure sensed by a digitiser using dedicated keyboard keys or combinations thereof
A keyboard entry system for use in a touch screen display in which a user touches the display to move a keyboard on the display. The user moves the keyboard until a desired key lies under a fixed cursor. To type the key, the user lifts his finger. The keyboard entry system generates data indicative of a selection of a desired character by the user in response to detection of an ending of a gesture by the user.
G06F 3/0488 - Interaction techniques based on graphical user interfaces [GUI] using specific features provided by the input device, e.g. functions controlled by the rotation of a mouse with dual sensing arrangements, or of the nature of the input device, e.g. tap gestures based on pressure sensed by a digitiser using a touch-screen or digitiser, e.g. input of commands through traced gestures
G06F 3/0481 - Interaction techniques based on graphical user interfaces [GUI] based on specific properties of the displayed interaction object or a metaphor-based environment, e.g. interaction with desktop elements like windows or icons, or assisted by a cursor's changing behaviour or appearance
G04G 21/08 - Touch switches specially adapted for time-pieces
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational services, namely, conducting conferences with national leaders from government, public education, public health, academia, media, industry, technology, philanthropy and advocacy in the field of developing a national plan for childhood obesity prevention, with particular focus on physical activity; entertainment services, namely, conducting contests designed to identify and reward program participants who set up and achieve goals exercising, making healthy eating choices, and engaging in other health-promoting activities; conducting educational research in connection with developing specific programs and curricula that can contribute to a national plan for childhood obesity prevention
39.
Three Dimensional Printing of Bio-Ink Compositions
3D printing of biopolymer-based inks provides for manufacturing a broad range of products with desirable properties. A print nozzle may be charged to form a cone-shaped ink droplet to result in increased resolution, more reliable contact with irregular surfaces, and a mechanism to control contacting the ink to the print surface.
Compositions and methods are provided for treating and/or preventing lymphangiogenesis in a subject by using an inhibitor of a galectin-8 protein in an amount effective to inhibit or to modulate an activity of the galectin-8 protein or a portion thereof sufficient to inhibit the lymphangiogenesis associated with cancer, corneal injury, dry eye disease, inflammation, lymphedema, organ rejection or graft rejection.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
41.
COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING MALNUTRITION
Provided herein are compositions and methods for treating, preventing, and reversing malnutrition. In particular, provided herein are compositions and methods for facilitating cognitive repair and preventing obesity (e.g. in children).
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
42.
HYBRID FLOW EVALUATION AND OPTIMIZATION OF THERMAL SYSTEMS
An approach to optimization of a thermal system includes applying computational fluid dynamics to precompute and store data for a set of canonical structures of heat transfer elements, and then using a flow network model to optimize dimensions and structures of the heat transfer elements of a thermal system in an optimization procedure that makes use of the stored data for the canonical structures.
F28F 13/12 - Arrangements for modifying heat transfer, e.g. increasing, decreasing by affecting the pattern of flow of the heat-exchange media by creating turbulence, e.g. by stirring, by increasing the force of circulation
G01R 21/00 - Arrangements for measuring electric power or power factor
G01R 21/06 - Arrangements for measuring electric power or power factor by measuring current and voltage
H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
H05K 7/00 - Constructional details common to different types of electric apparatus
H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating
43.
System and method for measuring phase delay and amplitude of a near infra-red signal in animal tissue
A system and method, for measuring phase delay and amplitude of a near infrared signal emanating from tissue of an animal subject in response a near infrared signal input to such tissue, operate by processing a signal from an optical detector and a corresponding signal from an optical detector emulation circuit. In some aspects, the processed signals are fed into zero crossing detectors that in turn feed a time-to-digital converter providing at an output thereof a digital measure of the phase delay of the received optical signal.
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
44.
Integrated circuit with multi-threshold bulk FinFETs
A method for manufacturing a FinFET having a fin that has a fin body includes selecting a desired electrical performance parameter, selecting a base dimension of the fin, identifying a combination of fin-body doping and fin-geometry that causes the FinFET to have the desired electrical performance parameter, doping the fin body according to the identified fin-body doping, and fabricating the fin according to the fin-geometry.
H01L 27/088 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including integrated passive circuit elements with at least one potential-jump barrier or surface barrier the substrate being a semiconductor body including only semiconductor components of a single kind including field-effect components only the components being field-effect transistors with insulated gate
H01L 29/78 - Field-effect transistors with field effect produced by an insulated gate
The present disclosure provides, among other things, systems for processing silk. Provided systems purify silk fibroin solutions without inducing conformational changes in the silk proteins. Provided systems concentrate silk fibroin solutions. The present disclosure also provides methods of purifying and concentrating silk fibroin solutions. Provided systems and methods are useful for processing silk fibroin for any application.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
In some embodiments, the present invention provides compositions including silk fibroin, at least one hydrophilic agent, and at least one catechol donating agent, wherein the at least one hydrophilic agent and at least one catechol donating agent are conjugated to the silk fibroin. According to various embodiments, at least a portion of the silk fibroin may be crosslinked. In some embodiments, the silk fibroin is at least 50% (e.g., 60%, 70%, 80%, 90%, 95% or more) crosslinked. In some embodiments, the present invention also provides methods for making such compositions.
A method of converting methane to an oxygenate. The method includes converting methane to an oxygenate with a transition metal ion loaded zeolite catalyst in an aqueous medium in the presence of gaseous O2 and CO at a temperature lower than 200°C. Also disclosed are a two-metal ion zeolite catalyst for converting methane to methanol and a method for preparing the two-metal ion zeolite catalyst.
C07C 29/48 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups
C07C 51/15 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
C07C 51/16 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation
The present invention includes methods of improving proteolytic stability of a polypeptide, comprising alkylating at least one selected from the group consisting of a N-terminus amino group, the NH group of the N-terminus first internal amide bond, another primary amino group, a thiol group and a thioether group within the polypeptide. The present invention further includes polypeptides incorporating such chemical modifications.
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
C07K 2/00 - Peptides of undefined number of amino acidsDerivatives thereof
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present invention includes methods of improving proteolytic stability of a polypeptide, comprising alkylating at least one selected from the group consisting of a N-terminus amino group, the NH group of the N-terminus first internal amide bond, another primary amino group, a thiol group and a thioether group within the polypeptide. The present invention further includes polypeptides incorporating such chemical modifications.
The present invention includes methods of improving proteolytic stability of a polypeptide, comprising alkylating at least one selected from the group consisting of a N-terminus amino group, the NH group of the N-terminus first internal amide bond, another primary amino group, a thiol group and a thioether group within the polypeptide. The present invention further includes polypeptides incorporating such chemical modifications.
A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
An apparatus for making music includes a cymbal, an acoustic transducer, a signal-processing system that receives a first signal from the acoustic transducer and that generates a second signal based on a property of the first signal, and a classifier that determines a particular manner in which the cymbal was struck based on the second signal, and provides an output trigger signal for triggering production of a sound that consistent with the particular manner.
G10H 3/10 - Instruments in which the tones are generated by electromechanical means using pick-up means for reading recorded waves, e.g. on rotating discs using capacitive pick-up means
G10D 13/06 - Castanets, cymbals, triangles, tambourines without drumheads or other single-toned percussion musical instruments
G10H 3/14 - Instruments in which the tones are generated by electromechanical means using mechanical resonant generators, e.g. strings or percussion instruments, the tones of which are picked up by electromechanical transducers, the electrical signals being further manipulated or amplified and subsequently converted to sound by a loudspeaker or equivalent device using mechanically actuated vibrators with pick-up means
A method for determining a hemoglobin saturation of a volume-oscillating vascular compartment in tissue includes receiving data representing measurements of a number of oscillating hemoglobin concentrations from the tissue and determining the hemoglobin saturation of the volume-oscillating vascular compartment to exclude an effect of an oscillating rate of supply of oxygenated blood to a portion of the tissue including removing a first contribution on one or more of the oscillating hemoglobin concentration measurements from at least one of the measurements, the first contribution being phase offset relative to said measurements.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
54.
MICROFLUIDIC DEVICES AND SYSTEMS FOR CELL CULTURE AND/OR ASSAY
Described herein are microfluidic devices and systems for high density cell culture and/or high throughput cell assays. Methods of using the same are also provided herein. In some embodiments, the microfluidic devices and systems described herein provide rapid and automated trapping of single embryos in ordered arrays.
A composite thread includes first and second segments joined to each other. The first segment comprises a functional segment that interacts with an environment of the thread. The second segment communicates information between the first segment and a point external to said composite thread.
The inventions provided herein relate to silk-based scaffolds and methods of producing the same, which can be used for a range of tissue engineering applications. The fabrication methods described herein provide a versatile platform to incorporate hollow conduits (e.g., for nutrient/oxygen delivery) through three-dimensional silk-based scaffolds that have tunable bulk properties (e.g., but not limited to, porosity, mechanical, degradation rate) and allow endothelialization and/or cell compartmentalization, for engineering a variety of complex tissue equivalents.
THE GENERAL HOSPITAL CORPORATION - DBA MASS GENERAL HOSPITAL (USA)
Inventor
Kaplan, David
Whalen, Michael
Hartnick, Christopher
Abstract
In some embodiments, the present invention provides methods for making resorbable ear tubes including the steps of providing a silk fibroin solution, and forming a silk ear tube from the silk fibroin solution, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbable. In some embodiments, the present invention also provides methods for treating otitis media including the step of introducing a silk ear tube into the ear canal of a subject, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbed by the subject.
THE GENERAL HOSPITAL CORPORATION - DBA MASS GENERAL HOSPITAL (USA)
Inventor
Kaplan, David
Whalen, Michael
Hartnick, Christopher
Abstract
In some embodiments, the present invention provides methods for making resorbable ear tubes including the steps of providing a silk fibroin solution, and forming a silk ear tube from the silk fibroin solution, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbable. In some embodiments, the present invention also provides methods for treating otitis media including the step of introducing a silk ear tube into the ear canal of a subject, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbed by the subject.
A61F 11/00 - Methods or devices for treatment of the ears or hearing sense Non-electric hearing aidsMethods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing senseProtective devices for the ears, carried on the body or in the hand
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
59.
ELECTROACTIVE SCAFFOLDS AND METHODS OF USING ELECTROACTIVE SCAFFOLDS
THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
TUFTS UNIVERSITY (USA)
Inventor
Hardy, John
Schmidt, Christine, E.
Kaplan, David, L.
Abstract
Embodiments of the present disclosure provide for conductive foams (e.g., silk foams, polymer foams) methods of making the conductive foam, method of using the conductive foam, and the like.
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
60.
ELECTROACTIVE SCAFFOLDS, METHODS OF MAKING ELECTROACTIVE SCAFFOLDS, AND METHODS OF USING ELECTROACTIVE SCAFFOLDS
THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
TUFTS UNIVERSITY (USA)
Inventor
Hardy, John
Schmidt, Christine, E.
Kaplan, David, L.
Abstract
Embodiments of the present disclosure provide for structures including an electroactive scaffold, methods of making the structure, method of using structure, and the like.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
61.
Electroactive biopolymer optical and electro-optical devices and method of manufacturing the same
A method of manufacturing a biopolymer optical device includes providing a polymer, providing a substrate, casting the polymer on the substrate, and enzymatically polymerizing an organic compound to generate a conducting polymer between the provided polymer and the substrate. The polymer may be a biopolymer such as silk and may be modified using organic compounds such as tyrosines to provide a molecular-level interface between the provided bulk biopolymer of the biopolymer optical device and a substrate or other conducting layer via a tyrosine-enzyme polymerization. The enzymatically polymerizing may include catalyzing the organic compound with peroxidase enzyme reactions. The result is a carbon-carbon conjugated backbone that provides polymeric “wires” for use in polymer and biopolymer optical devices. An all organic biopolymer electroactive material is thereby provided that provides optical functions and features.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
D01F 4/02 - Monocomponent artificial filaments or the like of proteinsManufacture thereof from fibroin
B29C 39/02 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor for making articles of definite length, i.e. discrete articles
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
G02B 6/138 - Integrated optical circuits characterised by the manufacturing method by using polymerisation
G02B 1/06 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of fluids in transparent cells
G01N 33/544 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements
THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
TUFTS UNIVERSITY (USA)
Inventor
Hardy, John
Schmidt, Christine, E.
Kaplan, David, L.
Abstract
Embodiments of the present disclosure provide for nonwoven mat of fibers (e.g., polycaprolactone fibers), method of making the nonwoven mat, method of using the nonwoven mat, and the like. In an embodiment, the fibers can be coated with an interpenetrating network of a conductive polymer and a dopant on the surface of the fibers.
Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant heteromultimeric neutralizing binding protein including two or multiple binding regions, such that the binding regions are not identical, and each binding region specifically binds a non-overlapping portion of the disease agent, thereby treating the subject for exposure to the disease agent. In a related embodiment, the heteromultimeric neutralizing binding protein includes two or multiple binding regions that neutralize a plurality of disease agents. In certain embodiments, the disease agent includes a bacterium, a bacterial protein, a virus, a viral protein, a cancer cell, and a protein or molecule produced therefrom. In certain embodiments, the disease agent is a plurality of different disease agents.
A polymer fiber formed of statistical copolymers, each of which contains zwitterionic repeat units and hydrophobic repeat units, the zwitterionic repeat units constituting 20-75 wt% of the statistical copolymer and the hydrophobic repeat units being characterized in that a homopolymer formed thereof has a glass transition temperature above room temperature. Also disclosed is a fibrous membrane containing such polymer fibers in which greater than 90% of the polymer fibers are each independently ribbon-shaped fibers or wrinkly fibers. A method of preparing such a fibrous membrane is disclosed as well.
A two-layer photo-responsive membrane including a polymer layer and a support layer, the polymer layer being disposed on a surface of the support layer. The polymer layer is formed of a graft copolymer that contains a hydrophobic backbone and multiple side chains, the side chains each consisting of repeat units that switch between a hydrophobic form and a hydrophilic form upon exposure to a light of a specific wavelength. The polymer layer has a molecular weight cut-off of 3,000 to 250,000 Daltons and a thickness of 50 nm to 10 µm; and the support layer has a molecular weight cut-off of 50 to 250,000 Daltons. Also disclosed is a method of preparing this two-layer photo-responsive membrane.
A macroporous polymeric hydrogel microsphere that contains poly(ethylene glycol), chitosan, and water. The hydrogel microsphere, having a diameter of 50-250 µm and a mesh size of 5-100 nm, is capable of transporting biomolecules conjugated to it. Also disclosed is a method of fabricating the microsphere based on a micromolding technique utilizing surface tension-induced droplet formation followed by photo-induced polymerization.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
D01F 4/02 - Monocomponent artificial filaments or the like of proteinsManufacture thereof from fibroin
C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
C12Q 1/28 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving peroxidase
B82Y 40/00 - Manufacture or treatment of nanostructures
D01F 4/00 - Monocomponent artificial filaments or the like of proteinsManufacture thereof
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
69.
COMPOSITIONS AND METHODS FOR PREVENTING COLORECTAL CANCER
Provided herein are compositions and methods for preventing and/or reducing the risk of colorectal cancer. In particular, provided herein are probiotic and small molecule agents and their use in preventing colorectal cancer.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
The present application relates to silk fibroin-based materials, methods for making and using the same. Provided materials exhibit shape memory characteristics while showing comparable or better volumetric swelling, biocompatibility and/or degradability when compared to current memory polymers derived from either natural or synthetic materials.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
D01F 4/02 - Monocomponent artificial filaments or the like of proteinsManufacture thereof from fibroin
The present application relates to silk fibroin-based materials, methods for making and using the same. Provided materials exhibit shape memory characteristics while showing comparable or better volumetric swelling, biocompatibility and/or degradability when compared to current memory polymers derived from either natural or synthetic materials.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
D01F 4/02 - Monocomponent artificial filaments or the like of proteinsManufacture thereof from fibroin
A two-layer membrane including a polymer layer and a support layer, the polymer layer being disposed on a surface of the support layer. The polymer layer, having a pore size of at most 50 nm and a thickness of 5 nm to 10 µm, is formed of an amphiphilic copolymer that contains both charged groups and hydrophobic groups. The support layer has a pore size of 3 nm to 10 µm, which is larger than the pore size of the polymer layer. Also disclosed is a process of filtering a liquid using the two-layer membrane described above.
B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
B01D 69/00 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor
16 - Paper, cardboard and goods made from these materials
Goods & Services
printed materials, namely, newsletters, pamphlets, journals, books, and written educational materials featuring news and information about veterinary research and nutrition
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational services, namely, providing a research resource website featuring non-downloadable articles, blogs, quizzes, and also featuring frequently asked questions, all in the field of veterinary nutrition for pet owners and their veterinary professionals
16 - Paper, cardboard and goods made from these materials
Goods & Services
printed materials, namely, newsletters, pamphlets, journals, books, and written educational materials featuring news and information about veterinary research and nutrition
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational services, namely, providing a research resource website featuring non-downloadable articles, blogs, quizzes, and also featuring frequently asked questions, all in the field of veterinary nutrition for pet owners and their veterinary professionals
77.
Uridine diphosphate derivatives, prodrugs, compositions and methods for treating neurodegenerative disorders
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
A graft copolymer including zwitterionic repeat units and hydrophobic repeat units, in which the zwitterionic repeat units constitute 2-60 wt% of the graft copolymer and each of the hydrophobic repeat units is characterized in that a homopolymer formed thereof is miscible with polyvinylidene fluoride, polysulfone, poly ether sulfone, polyvinyl chloride, or polyacrylonitrile, each of the hydrophobic repeat units not being a repeat unit of polyvinylidene fluoride. Also disclosed is a filtration membrane containing such a graft copolymer or a statistical copolymer that includes the same composition of repeat units as the graft copolymer. Further disclosed are methods of preparing the graft copolymer and the filtration membrane.
C08F 265/06 - Polymerisation of acrylate or methacrylate esters on to polymers thereof
C08L 51/06 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers grafted on to homopolymers or copolymers of aliphatic hydrocarbons containing only one carbon-to-carbon double bond
The present invention provides, among other things, a silk ceramic material having enzymatically cross-linked amino acid side chains to generate injectable and flexible foam ceramics. Provided are compositions and methods of producing soft, flexible ceramic foam with silk polymeric crosslinking to serve as binders. Materials have applications in osteochondral and dental replacement and repair.
Provided herein are methods and compositions for the treatment of wounds in a mammalian subject. Particularly, novel bioactive polypeptides are provided that promote tissue repair and regeneration, including the activation of/stimulation of wound healing and wound closure, stimulate keratinocyte and endothelial cell motility and/or proliferation.
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
Provided herein are methods and compositions for the treatment of wounds in a mammalian subject. Particularly, novel bioactive polypeptides are provided that promote tissue repair and regeneration, including the activation of/stimulation of wound healing and wound closure, stimulate keratinocyte and endothelial cell motility and/or proliferation.
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent, methods, compositions and kits having a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes at least one or a plurality of disease agents that are toxins, for example at least one of a Botulinum toxin or an Anthrax toxin.
Provided herein are methods and compositions for the treatment of wounds in a mammalian subject. Particularly, novel bioactive polypeptides are provided that promote tissue repair and regeneration, including the activation of/stimulation of wound healing and wound closure, stimulate keratinocyte and endothelial cell motility and/or proliferation.
A processing system cooperates with an atomic force microscope operating in ramp mode at a ramp frequency is configured to collect data indicative of at least one of physical and chemical properties of a sample. The system collects data indicative of probe movement at a frequency that is higher than the ramp frequency. This data comprises a second-order portion of the probe's signal. Based at least in part on the second-order portion, the processor obtains a parameter that is indicative at least one of a physical and a chemical property of a sample.
A processing system cooperates with an atomic force microscope operating in ramp mode at a ramp frequency is configured to collect data indicative of at least one of physical and chemical properties of a sample. The system collects data indicative of probe movement at a frequency that is higher than the ramp frequency. This data comprises a second-order portion of the probe's signal. Based at least in part on the second-order portion, the processor obtains a parameter that is indicative at least one of a physical and a chemical property of a sample.
The present invention provides novel inflatable and rigidizable support elements, and methods of manufacture and use thereof. In particular, the present invention provides inflatable and rigidizable support elements rapidly inflated and rigidized using an acrylic adhesive and UV light generated by combustion, which find use, for example, in rapidly deploying and supporting the wing of an aerial vehicle and wind turbine towers.
B64C 3/56 - Folding or collapsing to reduce overall dimensions of aircraft
B64C 39/02 - Aircraft not otherwise provided for characterised by special use
D06M 10/00 - Physical treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, e.g. ultrasonic, corona discharge, irradiation, electric currents or magnetic fieldsPhysical treatment combined with treatment with chemical compounds or elements
D06M 15/327 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds of unsaturated alcohols or esters thereof
E04H 12/00 - TowersMasts or polesChimney stacksWater-towersMethods of erecting such structures
H05G 2/00 - Apparatus or processes specially adapted for producing X-rays, not involving X-ray tubes, e.g. involving generation of a plasma
87.
COMPOSITIONS, METHODS AND KITS FOR TREATING COMPLEMENT RELATED DISORDERS
Compositions, methods and kits are provided for treating complement related disorders in a subject with protein in combination having protein fusions of at least two of a CD46 protein, a CD55 protein and a CD59 protein or with a recombinant chimeric protein having at least two of a CD46 protein, a CD55 protein and a CD59 protein or with nucleic acids encoding these proteins. The composition negatively modulates classical and alternative complement pathways thereby treating complement related disorder such as macular degeneration, age-related macular degeneration, diabetic retinopathy, inflammatory bowel disease, thyroiditis, cryoglobulinaemia, fetal loss, organ graft rejection, cancer, etc.
Compositions, methods and kits are provided for treating complement related disorders in a subject with protein in combination having protein fusions of at least two of a CD46 protein, a CD55 protein and a CD59 protein or with a recombinant chimeric protein having at least two of a CD46 protein, a CD55 protein and a CD59 protein or with nucleic acids encoding these proteins. The composition negatively modulates classical and alternative complement pathways thereby treating complement related disorder such as macular degeneration, age-related macular degeneration, diabetic retinopathy, inflammatory bowel disease, thyroiditis, cryoglobulinaemia, fetal loss, organ graft rejection, cancer, etc.
The present invention provides compositions and methods for printing a predetermined pattern on silk fibroin materials using water based “inks.” Such technique may be useful for micro- and nano-engineering applications.
The present invention provides, among other things, methods for producing platelets including the steps of providing a silk membrane about 2 µm and 100 µm thick, inclusive, contacting the silk membrane with a porogen to form a porous silk membrane comprising at least one silk wall defining a lumen, associating the porous silk membrane with stromal derived factor-1? and at least one functionalizing agent, forming a three dimensional silk matrix comprising interconnected pores wherein the pores have a diameter of between about 5 and 500 µm, inclusive, wherein the silk matrix is formed around at least a portion of the porous silk membrane, introducing a plurality of megakaryocytes to the silk matrix such that the megakaryocytes are located at least partially within the porous silk matrix, and stimulating the plurality of megakaryocytes to produce platelets. Also provided are various new compositions and methods of making those compositions.
3D printing of biopolymer-based inks provides for manufacturing a broad range of products with desirable properties. A print nozzle may be charged to form a cone-shaped ink droplet to result in increased resolution, more reliable contact with irregular surfaces, and a mechanism to control contacting the ink to the print surface.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
The present application provides novel methods for the fabrication of nanostructures. More specifically, the invention relates to direct electron beam lithography with the use of silk fibroin as “green” resists.
G03F 7/32 - Liquid compositions therefor, e.g. developers
G03F 7/038 - Macromolecular compounds which are rendered insoluble or differentially wettable
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor
93.
Disulfide compounds for delivery of pharmaceutical agents
3 are defined herein. Also disclosed are a nanocomplex that is formed of such a compound and a pharmaceutical agent, and a nanocomplex that is formed of a protein and a bioreducible compound.
C07C 323/12 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
C07B 45/06 - Formation or introduction of functional groups containing sulfur of mercapto or sulfide groups
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
94.
Compositions and methods for treating inflammatory diseases
The invention provides compositions and methods for treating inflammatory diseases, such as cardiac or hepatic inflammatory diseases, involving the use of parasite-derived neurotrophic factor (PDNF), or fragment of PDNF. The invention also provides compositions featuring PDNF, or a fragment thereof, and methods for using such compositions for the proliferation and/or mobilization of a stem cell (e.g., cardiac stem cell) or progenitor cell (e.g., hepatic progenitor cell). In one aspect, the invention provides a method of decreasing inflammation in a nonneuronal tissue of a subject. In another aspect, the invention provides a method of decreasing inflammation in a cardiac, liver, pancreas, or gastrointestinal tissue of a subject. In still another aspect, the invention provides a method of increasing expression of an anti-inflammatory factor in a non-neuronal cell or tissue.
Compositions and methods are provided for treating and/or preventing lymphangiogenesis in a subject by using an inhibitor of a galectin-8 protein in an amount effective to inhibit or to modulate an activity of the galectin-8 protein or a portion thereof sufficient to inhibit the lymphangiogenesis associated with cancer, corneal injury, dry eye disease, inflammation, lymphedema, organ rejection or graft rejection.
A field effect transistor having a channel that comprises three-dimensional graphene foam. The subject matter of the invention concerns a three dimensional field-effect transistor having a channel based on graphene foam and the use of ionic liquid as a gate. The graphene foam is made of a three-dimensional network of single and double layer graphene that extends in all the three dimensions. Metal contacts on either end of the graphene foam form the drain and source contacts of the transistor.
The present invention includes compositions and methods of co-transformation of naturally competent cells. In one aspect of the invention, a method is included for introducing nucleic acid sequences into one or more naturally competent cells in parallel. In other aspects, a heterogenic pool of co-transformed naturally competent cells and an apparatus for introducing two or more populations of nucleic acid sequences into a population of naturally competent cells in parallel are also included.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
The present application discloses biopolymer-based ink formulations that are useful for inkjet printing and other applications. Related methods are also disclosed.
Lactobacillus rhamnosus strain CNCM I-3690 for reducing diet-induced weight gain and/or diet-induced insulin resistance, and treating disorders resulting therefrom, such as overweight, obesity and obesity-related disorders in a subject.
A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
